In addition, NephroGenex expects to grant the underwriters a 30-day option to purchase up to an additional $4.5 million of shares of its common stock in connection with the offering. All of the shares in the offering will be sold by NephroGenex.
The offering is subject to market and other conditions, and there can be no assurance as to when or whether the offering may be completed.
Canaccord Genuity Inc. and JMP Securities LLC are acting as joint book-running managers for the proposed offering. In addition, Oppenheimer & Co. Inc. is participating as lead manager, and H.C. Wainwright & Co., LLC and Noble Life Science Partners are participating as co-managers in the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. A copy of the prospectus relating to the offering, when available, may be obtained upon request by contacting the Syndicate Department of Canaccord Genuity Inc., Attention: Syndicate Department, 99 High Street, 12th Floor, Boston, Massachusetts 02110, or by telephone/email at (800) 225-6201/ [email protected], or from JMP Securities LLC, Attention: Prospectus Department, 600 Montgomery Street, 10th Floor, San Francisco, California 94111, or by telephone at +1 (415) 835-8985.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
